Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13282750 | 0.83 | MEN1 (0.56) | PDE10ATDP1ALDH1A1KMT2AMEN1 | |
| SCHEMBL29890053 | 0.78 | DRD1 (0.43) | PDE10ATDP1ALDH1A1CYP1A2MAPT | |
| SCHEMBL2483965 | 0.78 | — | — | |
| SCHEMBL4938450 | 0.78 | TDP1 (0.51) | TDP1ALDH1A1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL243134 | 0.76 | ALDH1A1 (0.53) | TDP1ALDH1A1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL4008329 | 0.76 | PDE10A (0.51) | PDE10ATDP1ALDH1A1HTR1ASLC6A2 | |
| SCHEMBL13770269 | 0.76 | TDP1 (0.50) | TDP1ALDH1A1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL10807074 | 0.76 | TDP1 (0.50) | TDP1ALDH1A1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL11183197 | 0.76 | TDP1 (0.50) | TDP1ALDH1A1HTR1ASLC6A2SLC6A4 | |
| SCHEMBL15924716 | 0.76 | MAPK8 (0.52) | TDP1ALDH1A1HTR1ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105392777-B | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2020-09-22 | — | — | CN | disclosed |
| EP-3013796-B9 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEMICAL LTD (KR) | 2020-07-01 | — | — | EP | disclosed |
| EP-3628661-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEM, LTD. (KR) | 2020-04-01 | — | — | EP | disclosed |
| CN-109535155-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维公司 | 2019-03-29 | — | — | CN | disclosed |
| US-10221138-B2 | Biaryl derivatives as GPR120 agonists | LG CHEM, LTD. (KR) | 2019-03-05 | — | — | US | disclosed |
| CN-103958508-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维公司 | 2019-02-12 | — | — | CN | disclosed |
| CN-105793262-A | Bicyclic alkyne derivatives and uses thereof | 新加坡科技研究局 | 2016-07-20 | — | — | CN | disclosed |
| US-20160168096-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2016-06-16 | — | — | US | disclosed |
| EP-3013796-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG Life Sciences Ltd. (KR) | 2016-05-04 | — | — | EP | disclosed |
| CN-105392777-A | Biaryl derivatives as GRP120 agonists | LG LIFE SCIENCES LTD | 2016-03-09 | — | — | CN | disclosed |
| WO-2014209034-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2014-12-31 | — | — | WO | disclosed |
| CN-103958508-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC | 2014-07-30 | — | — | CN | disclosed |
| EP-1633750-B1 | SYNTHESIS OF 5-SUBSTITUTED 7-AZAINDOLES AND 7-AZAINDOLINES | EISAI R&D MAN CO LTD (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-7652137-B2 | Substitued azaindoline intermediate for use in the manufacture of 5-substituted 7-azaindolines and 5-substituted 7-azaindoles; pharmaceutical intermediates | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-7652137-B2 | Substitued azaindoline intermediate for use in the manufacture of 5-substituted 7-azaindolines and 5-substituted 7-azaindoles; pharmaceutical intermediates | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168096-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | GPR119, GLP1R, GIPR | PDE10A 1505/4885TDP1 4846/4885ALDH1A1 2063/4885 |
| US-10221138-B2 | Biaryl derivatives as GPR120 agonists | GPR119, GLP1R, GIPR | PDE10A 1505/4885TDP1 4846/4885ALDH1A1 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.